Koestler T P, Papsidero L D, Nemoto T, Chu T M
Cancer Res. 1981 Jul;41(7):2900-7.
Rabbits tolerant to human immunoglobulin G were used to raise antisera against the Raji cell-bound circulating immune complexes from human breast cancer sera. After solid-phase adsorption treatment with glutaraldehyde-cross-linked normal human plasma, acetone-extracted normal liver tissue powder, and glutaraldehyde-fixed Raji cells, one antiserum reacted specifically with breast tissue extracts but not with extracts of other tissues, as examined by a counterimmunoelectrophoresis technique. Immunological reactivity of the treated antiserum was removed by incubation with normal, primary, or metastatic breast tumor tissue extracts. Incubation with normal human serum or extracts derived from tissues other than the breast showed no neutralizing effect on the antibodies. This specific antiserum reagent was used in a modification of the Raji cell radioimmunoassay. Raji cells were incubated with sera from cancer patients or normal controls and then reacted with 125I-labeled F(ab')2 fraction of the treated antiserum reagent. The amount of 125I-F(ab')2 bound was then determined. Although all sera exhibited elevated circulating immune complexes by the conventional Raji cell radioimmunoassay, 14 of 18 breast carcinoma sera demonstrated a significant uptake when compared with the normal population group as opposed to five (three lung and two colon) of 29 other cancer sera examined (p less than 0.001). An immunologically reactive breast tissue-associated antigen, purified from malignant breast tumor or normal breast tissue extracts with the use of antiserum reagent, exhibited an apparent molecular weight of 85,000 by sodium dodecyl sulfate; polyacrylamide gel electrophoresis and a pI value of 4.9 +/- 0.2. These results demonstrated that a breast tissue-associated antigen rather than a breast tumor-associated neoantigen, was involved in circulating immune complexes of breast cancer patients as detected by Raji cell immunoassay. It also implied the occurrence of disease-related autoimmunity in human breast cancer.
用对人免疫球蛋白G耐受的兔子来制备抗血清,该抗血清针对来自人乳腺癌血清中与Raji细胞结合的循环免疫复合物。在用戊二醛交联的正常人血浆、丙酮提取的正常肝组织粉末和戊二醛固定的Raji细胞进行固相吸附处理后,通过对流免疫电泳技术检测发现,一种抗血清与乳腺组织提取物发生特异性反应,但与其他组织提取物无反应。用正常、原发性或转移性乳腺肿瘤组织提取物孵育后,处理后的抗血清的免疫反应性消失。用正常人血清或乳腺以外组织的提取物孵育对抗体无中和作用。这种特异性抗血清试剂用于改良的Raji细胞放射免疫测定。将Raji细胞与癌症患者或正常对照的血清孵育,然后与经处理的抗血清试剂的125I标记的F(ab')2片段反应。随后测定结合的125I-F(ab')2的量。尽管通过传统的Raji细胞放射免疫测定所有血清的循环免疫复合物均升高,但与正常人群组相比,18例乳腺癌血清中有14例显示出明显的摄取,而在检测的29例其他癌症血清中只有5例(3例肺癌和2例结肠癌)有明显摄取(p<0.001)。用抗血清试剂从恶性乳腺肿瘤或正常乳腺组织提取物中纯化的一种具有免疫反应性的乳腺组织相关抗原,通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳显示其表观分子量为85,000,等电点值为4.9±0.2。这些结果表明,通过Raji细胞免疫测定检测到的乳腺癌患者循环免疫复合物中涉及的是一种乳腺组织相关抗原而非乳腺肿瘤相关新抗原。这也暗示了人类乳腺癌中存在与疾病相关的自身免疫。